Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.
2.

Editorial overview: Antimicrobials: fighting bacterial infections in the 21st century-thinking outside of the box.

Pucci MJ, Dougherty TJ.

Curr Opin Microbiol. 2016 Oct;33:v-vii. doi: 10.1016/j.mib.2016.08.002. Epub 2016 Aug 24. No abstract available.

PMID:
27567402
3.
4.

Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay.

Nayar AS, Dougherty TJ, Ferguson KE, Granger BA, McWilliams L, Stacey C, Leach LJ, Narita S, Tokuda H, Miller AA, Brown DG, McLeod SM.

J Bacteriol. 2015 May;197(10):1726-34. doi: 10.1128/JB.02552-14. Epub 2015 Mar 2.

5.

Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.

Nayar AS, Dougherty TJ, Reck F, Thresher J, Gao N, Shapiro AB, Ehmann DE.

Antimicrob Agents Chemother. 2015 Jan;59(1):331-7. doi: 10.1128/AAC.04077-14. Epub 2014 Oct 27.

6.

Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.

Reck F, Ehmann DE, Dougherty TJ, Newman JV, Hopkins S, Stone G, Agrawal N, Ciaccio P, McNulty J, Barthlow H, O'Donnell J, Goteti K, Breen J, Comita-Prevoir J, Cornebise M, Cronin M, Eyermann CJ, Geng B, Carr GR, Pandarinathan L, Tang X, Cottone A, Zhao L, Bezdenejnih-Snyder N.

Bioorg Med Chem. 2014 Oct 1;22(19):5392-409. doi: 10.1016/j.bmc.2014.07.040. Epub 2014 Aug 4.

PMID:
25155913
7.

NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE.

Antimicrob Agents Chemother. 2014 May;58(5):2657-64. doi: 10.1128/AAC.02778-13. Epub 2014 Feb 24. Erratum in: Antimicrob Agents Chemother. 2014 Jul;58(7):4250.

8.

Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus.

Nava HR, Allamaneni SS, Dougherty TJ, Cooper MT, Tan W, Wilding G, Henderson BW.

Lasers Surg Med. 2011 Sep;43(7):705-12. doi: 10.1002/lsm.21112.

9.

Introduction.

Dougherty TJ.

Methods Mol Biol. 2010;635:1-6. doi: 10.1007/978-1-60761-697-9_1.

PMID:
20552336
10.

Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.

Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, Farley KA, Granskog K, Hardink JR, Huband MD, Kamicker BJ, Kaneko T, Knickerbocker MJ, Liras JL, Marra A, Medina I, Nguyen TT, Noe MC, Obach RS, O'Donnell JP, Penzien JB, Reilly UD, Schafer JR, Shen Y, Stone GG, Strelevitz TJ, Sun J, Tait-Kamradt A, Vaz AD, Whipple DA, Widlicka DW, Wishka DG, Wolkowski JP, Flanagan ME.

J Med Chem. 2009 Dec 10;52(23):7446-57. doi: 10.1021/jm900729s.

PMID:
19775168
11.

Purification of the large ribosomal subunit via its association with the small subunit.

Simons SP, McLellan TJ, Aeed PA, Zaniewski RP, Desbonnet CR, Wondrack LM, Marr ES, Subashi TA, Dougherty TJ, Xu Z, Wang IK, LeMotte PK, Maguire BA.

Anal Biochem. 2009 Dec 1;395(1):77-85. doi: 10.1016/j.ab.2009.07.042. Epub 2009 Jul 30.

PMID:
19646947
12.

Comparative genome analysis of high-level penicillin resistance in Streptococcus pneumoniae.

Tait-Kamradt AG, Cronan M, Dougherty TJ.

Microb Drug Resist. 2009 Jun;15(2):69-75. doi: 10.1089/mdr.2009.0891.

PMID:
19432519
13.

Photodynamic therapy for the treatment of periocular squamous cell carcinoma in horses: a pilot study.

Giuliano EA, MacDonald I, McCaw DL, Dougherty TJ, Klauss G, Ota J, Pearce JW, Johnson PJ.

Vet Ophthalmol. 2008 Sep;11 Suppl 1:27-34. doi: 10.1111/j.1463-5224.2008.00643.x.

PMID:
19046267
14.

A method to assay penicillin-binding proteins.

Pucci MJ, Dougherty TJ.

Methods Mol Med. 2008;142:131-41. doi: 10.1007/978-1-59745-246-5_11.

PMID:
18437311
15.

Identification of an inhibitor of the MurC enzyme, which catalyzes an essential step in the peptidoglycan precursor synthesis pathway.

Zawadzke LE, Norcia M, Desbonnet CR, Wang H, Freeman-Cook K, Dougherty TJ.

Assay Drug Dev Technol. 2008 Feb;6(1):95-103. doi: 10.1089/adt.2007.114.

PMID:
18315498
16.

Nucleotide sequence changes between Streptococcus pneumoniae R6 and D39 strains determined by an oligonucleotide hybridization DNA sequencing technology.

Williams SP, Tait-Kamradt AG, Norton JE, Albert TJ, Dougherty TJ.

J Microbiol Methods. 2007 Jul;70(1):65-74. Epub 2007 Mar 30.

PMID:
17477996
17.

Purpurinimide carbohydrate conjugates: effect of the position of the carbohydrate moiety in photosensitizing efficacy.

Pandey SK, Zheng X, Morgan J, Missert JR, Liu TH, Shibata M, Bellnier DA, Oseroff AR, Henderson BW, Dougherty TJ, Pandey RK.

Mol Pharm. 2007 May-Jun;4(3):448-64. Epub 2007 Mar 21.

PMID:
17373821
18.

Extensive and genome-wide changes in the transcription profile of Staphylococcus aureus induced by modulating the transcription of the cell wall synthesis gene murF.

Sobral RG, Jones AE, Des Etages SG, Dougherty TJ, Peitzsch RM, Gaasterland T, Ludovice AM, de Lencastre H, Tomasz A.

J Bacteriol. 2007 Mar;189(6):2376-91. Epub 2006 Dec 28.

19.

Cyclopentanone ring-cleaved pleuromutilin derivatives.

Springer DM, Bunker A, Luh BY, Sorenson ME, Goodrich JT, Bronson JJ, DenBleyker K, Dougherty TJ, Fung-Tomc J.

Eur J Med Chem. 2007 Jan;42(1):109-13. Epub 2006 Dec 6.

PMID:
17156897
20.

Nature: a rich source for developing multifunctional agents. Tumor-imaging and photodynamic therapy.

Pandey RK, Goswami LN, Chen Y, Gryshuk A, Missert JR, Oseroff A, Dougherty TJ.

Lasers Surg Med. 2006 Jun;38(5):445-67. Review.

PMID:
16788930
21.

A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma.

Oseroff AR, Blumenson LR, Wilson BD, Mang TS, Bellnier DA, Parsons JC, Frawley N, Cooper M, Zeitouni N, Dougherty TJ.

Lasers Surg Med. 2006 Jun;38(5):417-26.

PMID:
16788928
22.
23.
24.

Targets, targets everywhere--so where are the new antibacterial drugs?

Pucci MJ, Dougherty TJ, Barrett JF.

IDrugs. 2000 Mar;3(3):249-50. No abstract available.

PMID:
16103924
25.

American Society of Microbiology - 100th General Meeting.

Dougherty TJ, Pucci MJ, Zawadzke L, Barrett JF.

IDrugs. 2000 Aug;3(8):857-60.

PMID:
16059795
26.

What will genomics bring to the finish line?

Dougherty TJ, Pucci MJ, Davison DB, Barrett JF.

IDrugs. 2001 Apr;4(4):373-4. No abstract available.

PMID:
16015466
27.

Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy.

Bellnier DA, Greco WR, Nava H, Loewen GM, Oseroff AR, Dougherty TJ.

Cancer Chemother Pharmacol. 2006 Jan;57(1):40-5. Epub 2005 Nov 5.

PMID:
16001178
28.

98th General Meeting of the American Society for Microbiology. May 17-21, 1998; Atlanta, GA.

Dougherty TJ, Pucci MJ, Beaulieu D, Thanassi JA, Casperson ME, Ferraro CA, Barrett JF, Frosco M.

Expert Opin Investig Drugs. 1998 Sep;7(9):1539-57.

PMID:
15992051
29.

Why are there no new antibiotics?

Pucci MJ, Dougherty TJ, Barrett JF.

Expert Opin Investig Drugs. 1998 Aug;7(8):1233-5.

PMID:
15992026
31.

Methyl pyropheophorbide-a analogues: potential fluorescent probes for the peripheral-type benzodiazepine receptor. Effect of central metal in photosensitizing efficacy.

Chen Y, Zheng X, Dobhal MP, Gryshuk A, Morgan J, Dougherty TJ, Oseroff A, Pandey RK.

J Med Chem. 2005 Jun 2;48(11):3692-5.

PMID:
15916419
32.

Synthesis and photosensitizing efficacy of isomerically pure bacteriopurpurinimides.

Chen Y, Sumlin A, Morgan J, Gryshuk A, Oseroff A, Henderson BW, Dougherty TJ, Pandey RK.

J Med Chem. 2004 Sep 23;47(20):4814-7.

PMID:
15369384
33.

Antibacterial drug discovery & development summit.

Barrett JF, Dougherty TJ.

Expert Opin Investig Drugs. 2004 Jun;13(6):715-21.

PMID:
15174958
34.

Photodynamic therapy for sarcoma pulmonary metastases: a preclinical toxicity study.

Anderson TM, Dougherty TJ, Tan D, Sumlin A, Schlossin JM, Kanter PM.

Anticancer Res. 2003 Sep-Oct;23(5A):3713-8.

PMID:
14666668
35.
36.

Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy.

Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, Morgan J, Dougherty TJ, Prasad PN.

J Am Chem Soc. 2003 Jul 2;125(26):7860-5.

PMID:
12823004
37.

Structure-activity relationship of new octaethylporphyrin-based benzochlorins as photosensitizers for photodynamic therapy.

Graham A, Li G, Chen Y, Morgan J, Oseroff A, Dougherty TJ, Pandey RK.

Photochem Photobiol. 2003 May;77(5):561-6.

PMID:
12812301
38.

Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.

Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Pandey RK, Tsuchida T, Dougherty TJ.

Cancer Res. 2003 Apr 15;63(8):1806-13.

39.

A first comparative study of purpurinimide-based fluorinated vs. nonfluorinated photosensitizers for photodynamic therapy.

Gryshuk AL, Graham A, Pandey SK, Potter WR, Missert JR, Oseroff A, Dougherty TJ, Pandey RK.

Photochem Photobiol. 2002 Nov;76(5):555-9.

PMID:
12462653
40.

Identification of 113 conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae.

Thanassi JA, Hartman-Neumann SL, Dougherty TJ, Dougherty BA, Pucci MJ.

Nucleic Acids Res. 2002 Jul 15;30(14):3152-62.

41.
42.

A novel synthetic route to fused propenochlorin and benzochlorin photodynamic therapy probes.

Li G, Mehta R, Srikrishnan T, Nurco DJ, Tabaczynski WA, Alderfer JL, Smith KM, Dougherty TJ, Pandey RK.

Chem Commun (Camb). 2002 Jun 7;(11):1172-3.

PMID:
12109067
43.

Microbial genomics and novel antibiotic discovery: new technology to search for new drugs.

Dougherty TJ, Barrett JF, Pucci MJ.

Curr Pharm Des. 2002;8(13):1119-35. Review.

PMID:
12052223
44.

Pharmacogenomics--is there a role in antibiotic therapy?

Davison DB, Dougherty TJ, Barrett JF, Pucci M.

Pharmacogenomics J. 2002;2(1):14-6. No abstract available.

45.

An update on photodynamic therapy applications.

Dougherty TJ.

J Clin Laser Med Surg. 2002 Feb;20(1):3-7. Review.

PMID:
11902352
46.

2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for photodynamic therapy.

Lobel J, MacDonald IJ, Ciesielski MJ, Barone T, Potter WR, Pollina J, Plunkett RJ, Fenstermaker RA, Dougherty TJ.

Lasers Surg Med. 2001;29(5):397-405.

PMID:
11891727
47.

Bacteriopurpurinimides: highly stable and potent photosensitizers for photodynamic therapy.

Chen Y, Graham A, Potter W, Morgan J, Vaughan L, Bellnier DA, Henderson BW, Oseroff A, Dougherty TJ, Pandey RK.

J Med Chem. 2002 Jan 17;45(2):255-8.

PMID:
11784129
48.

Efflux in bacteria: what do we really know about it?

Ryan BM, Dougherty TJ, Beaulieu D, Chuang J, Dougherty BA, Barrett JF.

Expert Opin Investig Drugs. 2001 Aug;10(8):1409-22. Review.

PMID:
11772259
49.
50.

Synthesis of beta-galactose-conjugated chlorins derived by enyne metathesis as galectin-specific photosensitizers for photodynamic therapy.

Zheng G, Graham A, Shibata M, Missert JR, Oseroff AR, Dougherty TJ, Pandey RK.

J Org Chem. 2001 Dec 28;66(26):8709-16.

PMID:
11749598

Supplemental Content

Loading ...
Support Center